ERBB2 and breast cancer: They found that an increased miR-567 expression inhibited autophagy by targeting a key autophagy-related protein (ATG5), thus reversing trastuzumab resistance of breast cancer, while the knockdown of miR-567 expression induced resistance to anti-HER2 targeted therapy.